Pharmaceutical Research
Single intramuscular injection of peramivir reduces influenza infection
Published in TB and Outbreaks Week, March 14th, 2006
According to recent research published in the journal Antiviral Research, "In the event of an influenza outbreak, antivirals including the neuraminidase (NA) inhibitors, peramivir, oseltamivir, and zanamivir may provide valuable benefit when vaccine production is delayed, limited, or cannot be used.
"Here we demonstrate the efficacy of a single intramuscular injection of peramivir in the mouse influenza model. Peramivir potently inhibits the neuraminidase enzyme N9 from H1N9 virus in vitro with a 50% inhibitory concentration (IC50 ) of 1.3±0.4...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Avian Influenza
Exposure to sick or dead poultry associated with flu-like illness - Brucellosis Outbreaks
Brucellosis outbreak reported among livestock workers in Korea - Epidemiology
Extra-familial exposure source of TB infection in children in north-eastern Croatia - Listeria Outbreaks
Listeria outbreaks caused by processing equipment and deli meat cross-contamination - Typhoid Vaccines
Salmonella pathogenicity island-2 mutant oral typhoid vaccine is immunogenic - African Trypanosomiasis
WHO collaborates on development of tools to improve diagnosis of sleeping sickness - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
